Practical experience with a degludec/liraglutide fixed-ratio combination therapy

Abstract

The article presents clinical experience with Xultophy as a representative of the new class of antidiabetic agents. Fixed-ratio combinations of basal insulin analogue and GLP-1 receptor agonist significantly enhanced the therapeutic potential for patients with type 2 diabetes mellitus.

Keywords

• type 2 diabetes
• therapy intensification
• combination injection therapy
• degludec
• liraglutide